Vemurafenib has been used in clinical trials for treatment with BRAF-mutant melanoma, lung cancer, refractory or relapsed Hairy-Cell Leukemia, and other cancers as well, single or combined with other anti-cancer drugs (Mazieres et al., 2020; Tiacci et al., 2021; Schmitt et al., 2022). Here, BRAF is linked to melanoma.